Table 6. Molecular markers in combination for prognostic relevance within diffuse astrocytomas (WHO grade II).

Groups	Subgroups	Mean time (months) of OS (95% CI)	P-value
5hmC/IDH1 (IHC)	5hmCLow/IDH1NS: 5hmCLow/IDH1PS:	37 (95% CI, 21–53): 59 (95% CI, 41–77):	0.003
	5hmCHigh/IDH1NS: 5hmCHigh/IDH1PS	35 (95% CI, 22–48): 83 (95% CI, 69–96)
5hmC/P53	5hmCLow/P53High: 5hmCLow/P53Low:	40 (95% CI, 19–60): 31 (95% CI, 17–44):	0.014
	5hmCHigh/P53High: 5hmCHigh/P53Low	71 (95% CI, 53–87): 62 (95% CI, 48–76)
5hmC/KI67	5hmCLow/KI67High: 5hmCLow/KI67Low:	22 (95% CI, 6–38): 42 (95% CI, 26–58):	0.000
	5hmCHigh/KI67High: 5hmCHigh/KI67Low	63 (95% CI, 44–82): 80 (95% CI, 67–94)
P53/KI67	P53High/KI67High: P53High/KI67Low:	45 (95% CI, 18–72): 62 (95% CI, 42–83):	0.032
	P53Low/KI67High: P53Low/KI67Low	22 (95% CI, 12–33): 60 (95% CI, 43–73)
IDH1 (IHC)/P53	IDH1NS/P53High: IDH1NS/P53Low	41 (95% CI, 16–64): 33 (95% CI, 20–47):	0.083
	IDH1PS/P53High: IDH1PS/P53Low	68 (95% CI, 47–90): 64 (95% CI, 48–81)
IDH1 (IHC)/KI67	IDH1NS/KI67High: IDH1NS/KI67Low	38 (95% CI, 16–60): 60 (95% CI, 42–79):	0.086
	IDH1PS/KI67High: IDH1PS/KI67Low	57 (95% CI, 36–78): 75 (95% CI, 58–91)
5hmC/IDH1 (Seq)	5hmCLow/IDH1WT: 5hmCLow/IDH1Mut:	20 (95% CI, 6–33): 51 (95% CI, 34–68):	0.000
	5hmCHigh/IDH1WT: 5hmCHigh/IDH1Mut	51 (95% CI, 30–70): 79 (95% CI, 67–89)
IDH1 (Seq)/P53	IDH1WT/P53High: IDH1WT/P53Low	37 (95% CI, 12–62): 38 (95% CI, 18–59):	0.007
	IDH1Mut/P53High: IDH1Mut/P53Low	76 (95% CI, 61–90): 61 (95% CI, 48–73)
IDH1 (Seq)/KI67	IDH1WT/KI67High: IDH1WT/KI67Low	26 (95% CI, 11–40): 45 (95% CI, 21–70):	0.003
	IDH1Mut/KI67High: IDH1Mut/KI67Low	68 (95% CI, 51–84): 70 (95% CI, 57–82)
IDH1 (Seq)/IDH1 (IHC)	IDH1WT/IDH1NS: IDH1WT/IDH1PS	36 (95% CI, 20–52): 38 (95% CI, 10–66):	0.003
	IDH1Mut/IDH1NS: IDH1Mut/IDH1PS	85 (95% CI, 71–99): 65 (95% CI, 54–76)

OS, overall survival. IHC: immunohistochemistry; NS: negative staining; PS: positive staining; Mut: Mutation; WT: wild type; Seq: sequencing.